How Accenture and AWS are upgrading Merck’s IT and drug discovery R&D engine

[Pixel Matrix/Adobe Stock]

Historically, the pharma sector has exhibited a degree of caution in adopting emerging technologies such as cloud computing and AI, given the sector’s stringent regulatory requirements, data security concerns, and the complexities involved in integrating new systems into legacy processes.

The situation is beginning to shift considerably with the COVID-19 pandemic, in particular, acting as a catalyst, compelling many Big Pharma companies to accelerate their digital initiatives. Pfizer, Sanofi, Novartis, AstraZeneca, and other Big Pharma companies have unveiled ambitious initiatives tapping cloud computing and AI technologies, aiming to streamline various aspects of drug discovery and development.

Inside the Accenture-AWS-Merck pharma alliance

For instance, Merck in 2021 forged an alliance with Accenture and AWS to update its IT infrastructure and facilitate advanced drug discover…

Read more
  • 0